While earlier single-agent investigations of immune checkpoint inhibition (ICI) across lymphoma entities in the R/R setting were rather disappointing [109,110,111], 1L combinations of the PD1 blocker Pembrolizumab or the PD-L1 blocker Avelumab with R-CHOP produced encouraging PFS signals [112,113]. This evidence concerns the gene DDIT3 and lymphoma.